Showing results (541-550 of 784) with videos related to

Sort By:
Pageof 79
Rheumatology (Oxford, England)|October 3, 2022
Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritisRyan M Hum, Pauline Ho, Nisha Nair, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 11, 2009
A role of cellular prion protein in programming T-cell cytokine responses in diseaseRebecca J Ingram, Jeremy D Isaacs, Gurman Kaur, et al.
Archives of Disease in Childhood|April 1, 1992
Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation scheduleR Booy, S A Taylor, S R Dobson, et al.
Frontiers in Immunology|June 6, 2018
Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid ArthritisFaye A H Cooles, Amy E Anderson, Andrew Skelton, et al.
Arthritis Research & Therapy|May 18, 2006
Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic miceAlexei von Delwig, Catharien M U Hilkens, Daniel M Altmann, et al.
Chemistry of Materials : a Publication of the American Chemical Society|January 27, 2015
Mesoporous Silica Nanoparticles Coated by Layer-by-Layer Self-assembly Using Cucurbit[7]uril for in Vitro and in Vivo Anticancer Drug ReleaseQing-Lan Li, Yanfang Sun, Yu-Long Sun, et al.
The Journal of Clinical Endocrinology and Metabolism|July 7, 2012
Adrenal steroidogenesis after B lymphocyte depletion therapy in new-onset Addison's diseaseSimon H S Pearce, Anna L Mitchell, Stuart Bennett, et al.
Arthritis Research & Therapy|December 21, 2016
Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapiesFaye A H Cooles, Amy E Anderson, Tracey Drayton, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)|June 16, 2004
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitisConor C Murphy, Kathrin Greiner, Jarka Plskova, et al.
Annals of the Rheumatic Diseases|December 21, 2012
The role of biosimilars in the treatment of rheumatic diseasesThomas Dörner, Vibeke Strand, Gilberto Castañeda-Hernández, et al.
Pageof 79